Tokuyama Corporation
Fiscal Year Ending March 2026 Q3 Financial Results Briefing
Net sales of 251.5 billion yen (Year-over-Year -1%), operating income of 26.7 billion yen (Year-over-Year +27%), quarterly net income of 18.8 billion yen (Year-over-Year +12%), downward revision of full-year earnings guidance.
Key Figures
- Net Sales: 251.5 billion yen (Year-over-Year -1%)
- Operating Income: 26.7 billion yen (Year-over-Year +27%)
- Net Income Attributable to Owners of Parent for the Quarter: 18.8 billion yen (Year-over-Year +12%)
AI要約
Overview of Financial Results
Net sales for the third quarter of the fiscal year ending March 2026 were 251.5 billion yen, a 1% decrease compared to the same period last year. The consolidation of Tokuyama Life Sciences (TLS) Group and increased sales of semiconductor-related products contributed to revenue growth; however, declines in overseas market conditions for PVC-related products resulted in a net decrease. On the other hand, operating income rose 27% Year-over-Year to 26.7 billion yen due to manufacturing cost improvements and strong sales of semiconductor-related products. Quarterly net income was 18.8 billion yen, up 12% Year-over-Year.
Assets, Liabilities, and Earnings Guidance
Total assets increased to 556.3 billion yen (up 80.1 billion yen from the previous fiscal year-end), and shareholders’ equity reached 277.0 billion yen (up 15.5 billion yen), but the equity ratio declined to 49.8%. Interest-bearing debt increased to 163.8 billion yen (up 53.1 billion yen). Based on progress through the third quarter, the full-year earnings guidance for fiscal 2026 was revised downward to net sales of 351.5 billion yen (4% decrease from previous forecast), operating income of 39.0 billion yen (6% decrease), and net income of 27.5 billion yen (5% decrease).
